Publications by authors named "Elisabeth Schaeublin"

6Publications

Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI.

Am J Physiol Lung Cell Mol Physiol 2007 Mar 3;292(3):L644-53. Epub 2006 Nov 3.

Discovery Technologies Department, Novartis Institutes for BioMedical Research, Basel, Switzerland.

View Article and Find Full Text PDF
March 2007

Identification with MRI of the pleura as a major site of the acute inflammatory effects induced by ovalbumin and endotoxin challenge in the airways of the rat.

Am J Physiol Lung Cell Mol Physiol 2006 Oct 25;291(4):L651-7. Epub 2006 May 25.

Novartis Institutes for BioMedical Research, Discovery Technologies, Lichtstr. 35, WSJ-386.2.09, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
October 2006

Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging.

Eur J Pharmacol 2003 Dec;482(1-3):319-24

Discovery Technologies Center, Novartis Institutes for BioMedical Research, Lichstr. 35, WSJ-386.2.09, CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
December 2003

Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging.

Br J Pharmacol 2003 Sep 18;140(2):239-46. Epub 2003 Aug 18.

Novartis Institutes for Biomedical Research, Central Technologies, Analytics and Imaging Sciences Unit, Lichtstr. 35, WSJ-386.2.09 CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2003

Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen.

Naunyn Schmiedebergs Arch Pharmacol 2003 Jul 24;368(1):17-25. Epub 2003 Jun 24.

Novartis Institute for Biomedical Research, WSJ.386.508, 4002 Basel, Switzerland.

View Article and Find Full Text PDF
July 2003

Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats.

Biochem Biophys Res Commun 2002 Mar;292(1):216-21

Central Technologies, Novartis Pharma AG, Lichtstrasse 35, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2002